Compare Stocks → Exposed: 10 CENT Crypto to Explode April 20th? (From True Market Insiders) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:ACORNASDAQ:AGTCNASDAQ:CSBRNASDAQ:PSTI Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACORAcorda Therapeutics$0.66-24.9%$11.13$0.61▼$24.20$820K1.4119,299 shs416,900 shsAGTCApplied Genetic Technologies$0.39$0.39$0.23▼$2.83$26.62M1.55943,490 shsN/ACSBRChampions Oncology$5.26+4.0%$10.15$7.19▼$14.68$71.48M0.392,719 shs2,313 shsPSTIPluristem Therapeutics$1.24$0.95▼$3.45$32.35M1.91715,259 shs2,128 shs5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACORAcorda Therapeutics0.00%0.00%-94.54%-96.11%-92.97%AGTCApplied Genetic Technologies0.00%0.00%0.00%0.00%0.00%CSBRChampions Oncology+3.95%+2.73%-2.59%-13.77%+3.95%PSTIPluristem Therapeutics0.00%0.00%0.00%0.00%0.00%Exposed: 10 CENT Crypto to Explode April 20th? (Ad)The man who bought Bitcoin and Ethereum in 2017… and has spotted 44 different coins that have returned over 100%... Is now exposing a 10-cent coin that just partnered with Amazon…Click For My #1 FREE Crypto for 2024MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationACORAcorda TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AAGTCApplied Genetic TechnologiesN/AN/AN/AN/AN/AN/AN/AN/ACSBRChampions Oncology3.7635 of 5 stars3.34.00.04.60.62.50.0PSTIPluristem TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACORAcorda TherapeuticsN/AN/AN/AN/AAGTCApplied Genetic TechnologiesN/AN/AN/AN/ACSBRChampions Oncology2.50Moderate Buy$7.5042.59% UpsidePSTIPluristem TherapeuticsN/AN/AN/AN/ACurrent Analyst RatingsLatest CSBR, ACOR, PSTI, and AGTC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/13/2024CSBRChampions OncologyCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold(Data available from 4/24/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACORAcorda Therapeutics$117.63M0.01$33.05 per share0.02($127.17) per share-0.01AGTCApplied Genetic Technologies$320K83.19N/AN/A$0.26 per share1.51CSBRChampions Oncology$53.87M1.33N/AN/A$0.34 per share15.47PSTIPluristem Therapeutics$20K0.00N/AN/A$1.80 per share0.00Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACORAcorda Therapeutics-$252.85M-$203.83N/A∞N/A-214.95%-2,206.93%-83.28%5/9/2024 (Estimated)AGTCApplied Genetic Technologies-$68.94M-$1.46N/AN/AN/AN/A-192.90%-92.54%N/ACSBRChampions Oncology-$5.34M-$0.72N/A∞N/A-19.76%-850.72%-32.62%7/22/2024 (Estimated)PSTIPluristem Therapeutics-$49.87M-$1.47N/AN/AN/AN/A-100.63%-55.46%N/ALatest CSBR, ACOR, PSTI, and AGTC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/12/2024Q3 2024CSBRChampions OncologyN/A-$0.19-$0.19-$0.19N/A$12.02 millionDividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACORAcorda TherapeuticsN/AN/AN/AN/AN/AAGTCApplied Genetic TechnologiesN/AN/AN/AN/AN/ACSBRChampions OncologyN/AN/AN/AN/AN/APSTIPluristem TherapeuticsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACORAcorda Therapeutics3.070.330.26AGTCApplied Genetic Technologies0.391.401.40CSBRChampions OncologyN/A0.600.60PSTIPluristem Therapeutics0.578.228.22OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACORAcorda Therapeutics12.71%AGTCApplied Genetic Technologies22.05%CSBRChampions Oncology41.30%PSTIPluristem Therapeutics16.94%Insider OwnershipCompanyInsider OwnershipACORAcorda Therapeutics2.60%AGTCApplied Genetic Technologies4.10%CSBRChampions Oncology45.69%PSTIPluristem Therapeutics5.40%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableACORAcorda Therapeutics1111.24 million1.21 millionNo DataAGTCApplied Genetic Technologies8367.63 million64.86 millionOptionableCSBRChampions Oncology14313.59 million7.38 millionOptionablePSTIPluristem Therapeutics15332.35 million30.60 millionOptionableCSBR, ACOR, PSTI, and AGTC HeadlinesSourceHeadlineNBRVF Nabriva Therapeutics plcseekingalpha.com - August 18 at 10:08 PMPluri CEO Issues Shareholder Updatefinance.yahoo.com - July 25 at 8:14 AMPluristem Therapeutics Inc. Changes its Name to "Pluri Inc." Reflecting the Company's Strategy to Leverage its Innovative 3D Cell-based Technology Platform to Additional Industriesbenzinga.com - July 25 at 2:34 AMPluristem Therapeutics Inc. Changes its Name to “Pluri Inc.” Reflecting the Company’s Strategy to Leverage its Innovative 3D Cell-based Technology Platform to Additional Industriesfinance.yahoo.com - July 25 at 1:25 AMPluristem (PSTI) Phase III Study Misses Goal, Stock Downfinance.yahoo.com - July 14 at 4:41 PMPluristem Posts Mixed Results From Study Of Muscle Regeneration After Hip Fracture Surgeryfinance.yahoo.com - July 13 at 5:38 PMPluristem's Phase 3 Study Of PLX-PAD To Treat Muscle Injury Does Not Meet Primary Goalmarkets.businessinsider.com - July 13 at 7:28 AMPluristem Reports Topline Results from its Phase III Study of Muscle Regeneration Following Hip Fracture Surgeryfinance.yahoo.com - July 13 at 7:28 AMPluristem: Fiscal Q3 Earnings Snapshotapnews.com - May 10 at 2:20 PMPluristem and Tnuva to Ring Nasdaq Closing Bell in Honor of New Partnershipfinance.yahoo.com - March 28 at 7:49 AMPluristem PLX-R18 shows promise in blood cell recovery in cell transplant patients in trialseekingalpha.com - March 23 at 6:10 PMPluristem Releases PLX-R18 Hematology Phase I Study Results: Data Show Increase in All Blood Lines and Reduction in Blood Transfusionsfinance.yahoo.com - March 23 at 8:52 AMPluristem Therapeutics, Inc. Common Stock (PSTI)nasdaq.com - March 21 at 8:40 AMPluristem and Tnuva Appoint Food Tech Veteran Eyal Rosenthal as Chief Executive Officer of their New Joint Venturefinance.yahoo.com - March 8 at 9:53 AMPluristem Announce the Closing of its Collaboration with Tnuva Group to Establish Cultured Food Platformfinance.yahoo.com - February 24 at 8:48 AMPluristem: Fiscal Q2 Earnings Snapshottimesunion.com - February 8 at 7:12 PMWhat Are The Analysts’ Predictions For Pluristem Therapeutics Inc. (NASDAQ: PSTI)?stocksregister.com - January 18 at 3:31 PMThinking about buying stock in Pluristem Therapeutics, DiDi Global, Robinhood Markets, Bitfarms, or Adamis Pharmaceuticals?marketwatch.com - January 12 at 10:49 PMPluristem Therapeutics Inc. (NASDAQ: PSTI) Is On The Risestocksregister.com - January 11 at 2:09 PMPluristem Therapeutics Inc. (NASDAQ: PSTI) Must Gain 75.17% To Achieve Consensus Price Targetmarketingsentinel.com - January 10 at 6:05 PMIsrael's Tnuva partners with Pluristem to develop cultured cell-based meatmsn.com - January 10 at 1:04 PMBiotech Pluristem, Israel-Based Tnuva Collaborate On Cultured Food Platformfinance.yahoo.com - January 10 at 1:04 PMPluristem Climbs On Collaboration With Tnuva Of Israel For Commercialization Of Alternative Meatnasdaq.com - January 10 at 1:04 PMIs Pluristem Therapeutics (PSTI) Stock a Good Buy?cnafinance.com - January 10 at 1:04 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAcorda TherapeuticsNASDAQ:ACORAcorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in adults with multiple sclerosis; and Inbrija, an inhaled levodopa for intermittent treatment of OFF periods in people with Parkinson's disease treated with a carbidopa/levodopa regimen. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. The company's product pipeline includes Cimaglermin alfa (GGF2), a member of neuregulin growth factor family which is in Phase 1 clinical trials for recovery of neurological injury, as well as to enhance heart function in animal models of heart failure. In addition, it has collaboration and license agreement with Biogen Inc. for the development and commercialization of Ampyra. The company was incorporated in 1995 and is headquartered in Pearl River, New York.Applied Genetic TechnologiesNASDAQ:AGTCApplied Genetic Technologies Corporation, a clinical-stage biotechnology company, develops transformational genetic therapies for patients suffering from rare and debilitating diseases. Its advanced product candidates include three ophthalmology development programs across two targets, including X-linked retinitis pigmentosa, which is in the Phase 1/2 clinical trials; and achromatopsia that is in Phase 1/2 clinical trials. It is also developing an optogenetic product candidate to treat advanced retinal disease. In addition, the company has initiated one preclinical program in otology; preclinical program in dry age-related macular degeneration; and two preclinical programs in targeting central nervous system disorders, including frontotemporal dementia and amyotrophic lateral sclerosis. It has collaboration agreements with University of Florida; Bionic Sight, Inc.; and Otonomy, Inc. The company was incorporated in 1999 and is headquartered in Alachua, Florida.Champions OncologyNASDAQ:CSBRChampions Oncology, Inc. engages in the development and sale of technology solutions and products to personalize the development and use of oncology drugs. Its technology platform, TumorGraft, is a novel approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. It uses its technology to offer solutions to Translational Oncology Solutions, which includes pharmaceutical and biotechnology companies; and Personalized Oncology, which assists physicians in developing personalized treatment options for their cancer patients. The company was founded by James M. Martell and David Sidransky on June 4, 1985 and is headquartered in Hackensack, NJ.Pluristem TherapeuticsNASDAQ:PSTIPluristem Therapeutics Inc. operates as a bio-technology company. It focuses on the research, development, clinical trial, and manufacture of cell therapeutic products and related technologies for the treatment of various ischemic, inflammatory, and hematologic conditions, as well as autoimmune disorders. The company develops placental expanded (PLX) based cell therapy products, including PLX-PAD that is in Phase III clinical trial for the recovery after surgery for hip fracture; in Phase II clinical trail for the treatment of acute respiratory distress syndrome associated with COVID-19; and in Phase I/II clinical trial for treatment of steroid-refractory graft versus host disease. It also develops PLX-R18, which has completed Phase I clinical trial incomplete hematopoietic recovery following hematopoietic cell transplantation, as well as conducts various animal studies for the evaluation of PLX-R18 for the treatment of acute radiation syndrome. The company has a license agreement for conducting clinical trials of PLX-PAD product in South Korea. It also has a collaborative project nTRACK, that examines gold nano particles labeling of stem cells; and has collaboration agreement with the NASA's Ames Research Center to evaluate the potential of PLX cell therapies in preventing and treating medical conditions caused during space missions. Pluristem Therapeutics Inc. was incorporated in 2001 and is based in Haifa, Israel. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.